COPENHAGEN (Reuters) – Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.
The Danish drugmaker said in a stock announcement after market close on Friday that a contract manufacturer filling syringes for pens with its Wegovy drug had temporarily stopped deliveries and manufacturing after issues with good manufacturing practice.
(Reporting by Stine Jacobsen; Editing by David Goodman)
